Cat. No. | Species | Product Description | Structure | Purity | Feature |
---|---|---|---|---|---|
CD4-HF2H7 | Human | FITC-Labeled Human CD4 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD4-HF255 | Human | FITC-Labeled Human CD4 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD4-H82E8 | Human | Biotinylated Human CD4 Protein, His,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
CD4-H82F3 | Human | Biotinylated Human CD4 Protein, Fc,Avitag™ | ![]() |
![]() ![]() |
![]() ![]() |
CD4-C5256 | Rhesus macaque | Rhesus macaque CD4 Protein, Fc Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD4-C52H7 | Rhesus macaque | Rhesus macaque CD4 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
LE3-H5228 | Human | Human CD4 / LEU3 Protein, His Tag | ![]() |
![]() ![]() |
![]() ![]() |
CD4-H5259 | Human | Human CD4 Protein, Fc Tag (MALS verified) | ![]() |
![]() ![]() ![]() ![]() |
![]() ![]() |
2e5 of CD4-CAR-293 cells were stained with 100 μL of 0.3 μg/mL of FITC-Labeled Human CD4, His Tag (Cat. No. CD4-HF2H7) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested).
Immobilized Ibalizumab (Human IgG4) at 1 μg/mL (100 μL/well) can bind FITC-Labeled Human CD4, Fc Tag (Cat. No. CD4-HF255) with a linear range of 20-313 ng/mL (QC tested).
The purity of Human CD4, Fc Tag (MALS verified) (Cat. No. CD4-H5259) was more than 95% and the molecular weight of this protein is around 150-170 kDa verified by SEC-MALS.
Immobilized Human CD4, Fc Tag (Cat. No. CD4-H5259) at 1 μg/mL (100 μL/well) can bind Ibalizumab (Human IgG4) with a linear range of 0.2-3 ng/mL (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Ibalizumab-uiyk | 5AB; Hu5A8; TMB-355; TNX-355 | Approved | Biogen, TaiMed Biologics, Theratechnologies | TROGARZO | fda | TAIMED BIOLOGICS USA | 2018-03-06 | HIV infection | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Anti-CD4 monoclonal antibody (Immunotech) | Phase Ⅱ | Immunotech | HIV infection | Details | |
F-105 | F-105 | Phase Ⅰ | Centocor | HIV infection | Details |
EC-18 | EC-18 | Phase Ⅱ | Enzychem Lifesciences | Neutropenia | Details |
PRO-542 | PRO-542 | Phase Ⅱ | Columbia University, Progenics Pharmaceutical | HIV infection | Details |
GEN-009 | GEN-009 | Phase Ⅱ | Genocea Biosciences | Solid tumours | Details |
ITV 1(Nonindustrial source) | ITV-1 | Phase Ⅲ | Nonindustrial source, Immunotech Laboratories, Synexa Life Sciences | HIV infection | Details |
Cedelizumab | Phase Ⅱ | Ortho-McNeil | Autoimmune diseases, Transplant rejection | Details | |
TMB-365 | TMB-365 | Phase Ⅰ | TaiMed Biologics | HIV infection | Details |
802-2 | 802-2; Anti-CD4 802-2; cnscqic-cyclic | Phase Ⅱ | Thomas Jefferson University, Synthetic Biologics | Graft versus host disease | Details |
Radiolabeled anti-CD4 monoclonal antibody fragment (Biotectid) | EP-1645 | Phase Ⅱ | BIOTECTID | Carotid stenosis, Rheumatoid arthritis (RA) | Details |
Zanolimumab | HuMaxCD4; MDX-CD4; MDX-016 | Phase Ⅲ | Genmab, Emergent BioSolutions | Cutaneous T cell lymphoma (CTCL), Rheumatoid arthritis (RA) | Details |
Anti-CD4 monoclonal antibody 4162W94 | Phase Ⅱ | GlaxoSmithKline | Rheumatoid arthritis (RA) | Details | |
Clenoliximab | IDEC 151; SB-217969,SB 217969 | Phase Ⅱ | Biogen Idec | Psoriasis, Rheumatoid arthritis (RA), Asthma | Details |
HIV-1 peptide vaccine (microparticulate/monovalent, UBI) | Phase Ⅰ | United Biomedical | HIV infection | Details | |
RAP-102 | RAP-102; KLH-RAP 101,RAP 102,RAP102 | Phase Ⅰ | RAPID Pharmaceuticals | HIV infection, Multiple sclerosis (MS) | Details |
VRC-HIVMAB091-00-AB | N6LS; VRC-HIVMAB091-00-AB; Z258‐N6LS | Phase Ⅰ | National Institute of Allergy and Infectious Diseases | HIV infection | Details |
CD4 CAR T cell therapy (iCell Gene Therapeutics) | Phase Ⅰ | iCell Gene Therapeutics | Multiple myeloma (MM) | Details | |
IT-1208 (Kyowa Hakko Kirin) | IT-1208 | Phase Ⅰ | Kyowa Hakko Kirin, Ono Pharmaceutical | Solid tumours | Details |
VRC-HIVAAV070-00-GT | AAV8-VRC07 | Phase Ⅰ | National Institute of Allergy and Infectious Diseases | HIV infection | Details |
CEL-1000 | CEL-1000 | Preclinical | CEL-SCI | Malaria, West nile virus infection, Smallpox infection, HBV infection, Venezuelan equine encephalitis virus infection, Herpes simplex virus (HSV) infection | Details |
T-allo-10 | T-allo-10 | Phase Ⅰ | Stanford University | Graft versus host disease | Details |
CD4-directed chimeric antigen receptor engineered T-cells (Stony Brook University) | CD4CAR | Phase Ⅰ | Stony Brook University School of Medicine, University of Louisville, iCell Gene Therapeutics | Leukemia, T cell lymphoma | Details |
HuB-F5 antibody (Diaclone) | Phase Not Specified | Tepnel Pharma | Rheumatoid arthritis (RA) | Details | |
CALRLong36 peptide (Herlev Hospital) | Phase Ⅰ | Herlev Hospital | Myeloproliferative neoplasms | Details | |
BG-8962 | BG-8962 | Phase Ⅰ | National Institute of Allergy and Infectious Diseases | HIV infection | Details |
Anti-CD4 idiotype vaccine (Nonindustrial source) | Phase Ⅱ | Nonindustrial source | HIV infection | Details | |
Priliximab | CEN-000029; cMT-412; MT-412 | Phase Ⅱ | Centocor | Rejection in heart transplantation, Multiple sclerosis (MS), Rheumatoid arthritis (RA), Crohn's disease, Non-Hodgkin's lymphoma (NHL) | Details |
3BNC-117 | 3BNC-117 | Phase Ⅱ | Rockefeller University | HIV infection | Details |
Anti-CD4 monoclonal antibody (Tolerx) | TRX-1 (Tolerx); MTRX-1011A; RG-7424 | Phase Ⅰ | University of Oxford, Genentech, Tolerx | Cutaneous lupus erythematosus, Autoimmune diseases, Rheumatoid arthritis (RA) | Details |
RB-0003 | RB-0003 | Phase Ⅱ | BioNTech, TRON | Melanoma | Details |
LCAR-T2C CAR-T cell therapy (Nanjing Medical University) | Phase Ⅰ | The First Affiliated Hospital with Nanjing Medical University | T cell lymphoma | Details | |
Tregalizumab | BT-061; hB-F5 | Phase Ⅱ | Biotest, Abbvie, Boehringer Ingelheim | Plaque psoriasis, Rheumatoid arthritis (RA) | Details |
R-95288 | R-95288; SA-1080; S-1443; RKS-1443,R 95288; SA 1080; S 1443; RKS 1443,R95288; SA1080; S1443; RKS1443 | Phase Ⅰ | Daiichi Sankyo | HIV infection | Details |
Anti-CD4 CAR T-cell therapy (University of Pennsylvania) | CAR-C34ZFN | Phase Ⅰ | University of Pennsylvania | HIV infection | Details |
VRC-01-LS | VRC-HIVMAB-080-00-AB; VRC-01-LS | Phase Ⅰ | National Institute of Allergy and Infectious Diseases, Xencor | HIV infection | Details |
RBC-CD4 (Sheffield Medical Technologies) | Phase Ⅱ | Sheffield Pharmaceuticals | HIV infection | Details | |
Keliximab | SB-210396; IDEC-CE9.1,SB 210396 | Phase Ⅲ | Biogen, GlaxoSmithKline | Rheumatoid arthritis (RA), Asthma | Details |
VRC-07-523 | VRC-07-523; VRC-07-523-L S; VRC-HIVMAB-075 -00-AB; VRC-HIVMAB075-00-AB | Phase Ⅰ | National Institutes of Health | HIV infection | Details |
Anti-CD3 anti-CD20 bispecific antibody (Genmab) | GEN-3013 | Phase Ⅱ | Genmab | hematological malignancies | Details |
UB-421 | dB4; mAb-B4; UB-421 | Phase Ⅲ | United Biomedical, United BioPharma | HIV infection | Details |
HIV vaccines polytope (Bavarian Nordic/VaxOnco) | EP-1232; EP-1233; MVA-BN32; MVA-mBN32 | Phase Ⅱ | Bavarian Nordic, KAEL-GemVax | HIV infection | Details |
AVR-01 | AVR-01 | Phase Ⅰ | AVROBIO | Acute myeloid Leukemia (AML) | Details |
3-BNC-117-LS (Rockefeller University) | 3-BNC-117-LS | Phase Ⅰ | Rockefeller University | HIV infection | Details |
MVA-EL | MVA-EBNA1/LMP2 | Phase Ⅱ | Cancer Research UK, Chinese University of Hong Kong (CUHK) | Nasopharyngeal cancer | Details |
T cell gene therapy (Cell Genesys) | Phase Ⅱ | Cell Genesys | HIV infection, Colorectal cancer | Details |
This web search service is supported by Google Inc.